The FDA has accepted for review Chiesi’s New Drug Application (NDA) for their investigational maintenance treatment for ...
The regulator says the drug, whose generic name is Bupivacaine, failed to deliver its intended pharmacological effect ...
SCOTTSDALE, Ariz., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...
CAMBRIDGE, MA / ACCESSWIRE / February 24, 2022 / IIOT-OXYS Inc. (OTC PINK:ITOX) announces the execution of a Non-Disclosure Agreement (NDA) with a strategic European medical device ...
World leader in drug development to support companies with their device related regulatory issues in light of evolving r The NDA Group today announced the creation of a new division focusing on advice ...
One of the suspects was found with a sack of government drugs hidden in a boutique in Masaka city.